Found 1 Presentation For Request "1325p"
1325P - Sunvozertinib as first-line treatment in NSCLC patients with EGFR Exon20 insertion mutations
- James Chih-Hsin Yang (Taipei City, Taiwan)
Abstract
Background
Sunvozertinib (DZD9008) is a rationally designed, irreversible EGFR inhibitor targeting
Methods
NSCLC patients with
Results
As of February 21, 2023, a total of 28 patients were included in the efficacy analysis (200 mg, n = 19; 300 mg, n = 9). Median age was 67 years, and 75.0% (21/28) were female. Baseline ECOG PS was 0 or 1. Majority of patients (96.4%, 27/28) had metastatic diseases at study entry, with 21.4% (6/28) having > 3 metastatic sites and 32.1% (9/28) having baseline brain metastasis (BM). The most frequent mutation subtypes included 769_ASV (39.3%, 11/28), 770_SVD (10.7%, 3/28) and others. By IRC, 20 patients achieved tumor response, with a best objective response rate (ORR) of 71.4% (200 mg, 68.4%; 300 mg, 77.8%). Median duration of response has not been reached. Safety findings were consistent with results of previous sunvozertinib studies. The most common TEAEs included diarrhea, CPK increase, and skin rash. Majority of the AEs were of CTCAE grade 1 or 2, and clinically manageable.
Conclusions
In the 1st line setting, sunvozertinib as monotherapy demonstrated promising anti-tumor efficacy and acceptable safety profile in NSCLC patients with
Clinical trial identification
NCT03974022, NCT05559645.
Legal entity responsible for the study
Dizal Pharmaceutical.
Funding
Dizal Pharmaceutical.
Disclosure
All authors have declared no conflicts of interest.